Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
10.36
-0.24 (-2.26%)
At close: Dec 5, 2025, 4:00 PM EST
10.56
+0.20 (1.93%)
After-hours: Dec 5, 2025, 7:17 PM EST
Verastem Revenue
Verastem had revenue of $11.24M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $13.38M, up 33.79% year-over-year. In the year 2024, Verastem had annual revenue of $10.00M.
Revenue (ttm)
$13.38M
Revenue Growth
+33.79%
P/S Ratio
46.94
Revenue / Employee
$171,526
Employees
78
Market Cap
799.60M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VSTM News
- 10 days ago - Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference - Business Wire
- 22 days ago - Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
- 22 days ago - Verastem Oncology Announces Proposed Public Offering of Common Stock - Business Wire
- 4 weeks ago - Verastem Oncology to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 6 weeks ago - Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors - Business Wire
- 6 weeks ago - Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 - Business Wire